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In-vivo Proton Magnetic Resonance
Spectroscopy in Adnexal Lesions
Objective: To explore the in-vivo
1H- MR spectral features of adnexal lesions
and to characterize the spectral patterns of various pathologic entities.
Materials and Methods: Thirty-one patients with surgically and histopathologi-
cally confirmed adnexal lesions underwent short echo-time STEAM (stimulated
echo acquisition method) 
1H- MR spectroscopy, and the results obtained were
analysed.
Results: The methylene present in fatty acid chains gave rise to a lipid peak of
1.3 ppm in the 
1H- MR spectra of most malignant tumors and benign teratomas.
This same peak was not observed, however, in the spectra of benign ovarian
epithelial tumors: in a number of these, a peak of 5.2 ppm, due to the presence of
the olefine group (-CH=CH-) was noted. The ratios of lipid peak at 1.3 ppm to
water peak (lipid/water ratios) varied between disease groups, and in some
benign teratomas was characteristically high.
Conclusion: An intense lipid peak at 1.3 ppm is observed in malignant ovarian
tumors but not in benign epithelial tumors. 
1H- MRS may therefore be helpful in
the differential diagnosis of adnexal lesions.
ost adnexal lesions manifest as cystic masses and differential diagnosis on
the basis of imaging findings is difficult. Ultrasonography with color
Doppler is currently the standard imaging tool for the differential diagno-
sis of adnexal masses, and although very sensitive in detecting these and sometimes
able to indicate malignancy, it is frequently unable to provide images adequate for
specific diagnosis. Physical examinations and the CA 125 serum level are helpful in
some cases, and CT and MR imaging are increasingly used to evaluate pelvic masses;
malignancy can in some cases be predicted, but since tumors can be graded and histo-
logically assessed to only a limited extent, the results are no better than those obtained
with ultrasonography (1 6).
Localized in-vivo proton magnetic resonance spectroscopy (
1H- MRS) has been
shown to provide information about the contents of organic compounds in living tis-
sues, providing details of tumor metabolism that might well assist tumor grading and
lead to a better understanding of the biochemical pathways found within a lesion (7
14). As for ovarian tumors, however, the use of 
1H- MRS has -because of technical dif-
ficulty- been limited to in-vitro studies such as the analysis of aspirated fluid samples
(11). The in-vitro
1H- MR spectrum shows significantly different metabolite concentra-
tions between benign and malignant ovarian cysts: in the latter, significantly higher
levels of lactate, isoleucine, valine, 3-hydroxybutylic acid, methionine, and alanine are
detected. The recent use of short echo-time (TE) 
1H- MRS has facilitated the observa-
tion of macromolecules and lipids, in addition to small molecules. For lipids to give rise
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Mto a resonance peak that is narrow enough to be detectable
by in-vivo
1H- MRS, their fatty acyl chains must have a sig-
nificant degree of mobility, and such lipids are therefore
described as “mobile” (12). In tumors of the brain and
uterine cervix, an elevated lipid peak, as demonstrated by
1H- MRS, is thought to be a possible indicator of malignan-
cy (12, 13): in 
1H- MR spectra of these tumors, the pres-
ence of the methylene group, CH3, at 1.3 ppm, and the ole-
fine group, -CH=CH-, at 5.2 ppm, is observed in those that
are malignant.
In adnexal lesions, the acquisition of a good quality in-vi-
vo
1H- MR spectrum is very difficult because of motion ar-
tifacts caused by respiratory and bowel movements.
Moreover, 
1H- MR spectroscopy using STEAM with short
echo-time might be a more difficult and complex process
due to its lower signal-to-noise ratio (SNR) during data ac-
quisition and post-processing. The purpose of this study is
to explore the in-vivo
1H- MR spectral features of adnexal
lesions using short echo-time and to characterize the spec-
tral patterns of various pathologic entities.
MATERIALS AND METHODS
Patients
Thirty-one patients aged 22 69 (mean SD, 40 14)
years with surgically proven adnexal lesions were included
in this study. There were seven primary or secondary ma-
lignant ovarian tumors (2 papillary serous cystadenocarci-
nomas, 1 mucinous cystadenocarcinoma, 1 sarcomatoid
carcinoma, and 3 metastatic adenocarcinomas), one bor-
derline malignant mucinous cystic tumor, six benign ep-
ithelial tumors (3 mucinous cystadenomas, 1 serous cys-
tadenoma, 1 serous cystadenofibroma, and 1 benign mixed
epithelial tumor), eleven benign teratomas, four en-
dometrioses, one ectopic pregnancy, and one case of salp-
ingitis (Table 1). The maximal diameter of the lesions
ranged from 4 to 23 cm, which in all cases was greater than
the localization voxel for 
1H- MRS. Prior to 
1H- MRS,
Cho et al.
106 Korean J Radiol 3(2), June 2002
Table 1. In-vivo




Peak at 1.3 ppm Peak at 5.2 ppm Lipid/Water Ratio
01 54 Yes No 0.007 Papillary serous cystadenocarcinoma
02 61 Yes No 0.009 Papillary serous cystadenocarcinoma
03 50 Yes No NA Mucinous cystadenocarcinoma
04 61 No No NA Sarcomatoid carcinoma
05 62 Yes No 0.006 Metastatic adenocarcinoma
06 48 Yes No 0.007 Metastatic adenocarcinoma0
07 45 No No NA Metastatic adenocarcinoma
08 29 Yes No 0.006 Borderline malignant mucinous cystic tumor
09 57 No No 0.011 Mucinous cystadenoma
10 52 No No NA Mucinous cystadenoma
11 28 No No NA Mucinous cystadenoma
12 45 No No 0.005 Serous cystadenoma
13 25 No No 0.006 Serous cystadenofibroma
14 25 No No 0.007 Benign mixed epithelial tumor
15 42 Yes No 0.013 Teratoma
16 37 Yes No 0.341 Teratoma
17 29 Yes No 0.005 Mature cystic teratoma
18 39 Yes No 0.061 Mature cystic teratoma
19 22 Yes No 0.071 Mature cystic teratoma
20 31 Yes No 0.273 Mature cystic teratoma
21 23 Yes No 0.319 Mature cystic teratoma
22 36 No Yes 0.005 Mature cystic teratoma
23 52 No Yes 0.008 Mature cystic teratoma
24 25 No No 0.004 Mature cystic teratoma
25 36 No No 0.007 Mature cystic teratoma
26 25 No Yes 0.006 Endometriosis
27 40 No Yes 0.007 Endometriosis
28 30 No No 0.004 Endometriosis
29 24 No No 0.006 Endometriosis
30 69 Yes No 0.010 Acute and chronic salpingitis with necrosis
31 44 No Yes 0.010 Ectopic Pregnancy
Note.─ NA= not availablepelvic CT and/or MRI was performed in all patients, none
of whom has undergone treatment or biopsy. 
MR Spectroscopy 
For in-vivo
1H- MRS, a 1.5-T whole-body GE MRI/MRS
system (Signa Horizon; General Electric Medical Systems,
Milwaukee, Wis., U.S.A.) equipped with active shielded
gradients was used. Prior to 
1H- MRS, pelvic CT or MRI
findings were reviewed by a radiologist to determine the
location of adnexal lesions. MR imaging using a fast multi-
planar spoiled gradient-echo (FMPSPGR) sequence
(TR/TE= 100/1.5, NEX=1, matrix size=256 128, slice
thickness=8.0 mm, interslice gap=2.0 mm) was performed
in which the localization voxel was placed on the adnexal
lesion. Voxel size was approximately 8 cm
3 (2 2 2cm),
and the voxel was located safely within the lesion in order
to reduce contamination from adjacent normal tissue. For
all spectra, a STEAM (stimulated echo acquisition method)
localization sequence combined with a three-pulse CHESS
(chemical shift selective sequence) to suppress the H2O sig-
nal was used, and the acquisition parameters were as fol-
lows: TR=3000 ms, TE=30 ms, number of scans=128, and
number of excitations=1. During spectroscopic signal ac-
quisition, the subjects respired quietly without interrup-
tion. Respiratory gating was not used in this study. 
Spectral Analysis and Statistical Methods
Post-processing involving the use of a SUN SPARC 20
workstation with Spectral Analysis/General Electric
(SA/GE) software; incorporated in this were low-frequency
filtering of residual water signal, apodization by 0.5 Hz of
exponential line broadening, zerofilling of 8000, Fourier
transformation, and lorenzian-to-gaussian transformation.
1H- MR spectra both with and without water-peak sup-
pression were obtained, and all spectra were analysed with
particular attention to the presence of lipid peaks at 1.3
and 5.2 ppm, and a water peak at 4.77 ppm. Lipid/water
ratios were calculated by integrating the peak area of the
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Fig. 1. Patient 2. Mucinous cystadenocarcinoma in a 61-year old woman. (A) Gadolinium-enhanced axial MR image and (B) axial
scanogram obtained using 
1H- MRS reveal a cystic tumor with a solid nodular component. A prominent lipid peak occurred at about 1.3
ppm in (C) water-unsuppressed and (D) water-suppressed spectra, and the calculated lipid-to-water ratio was 0.009.
CDlipid peak at 1.3 ppm and water peaks in water-unsup-
pressed spectra. In spectra that demonstrated a dominant
lipid peak at about 1.3 ppm, the highest peak point 0.3
ppm of both the lipid and water peak was integrated. In
1H- MR spectra that showed no dominant lipid peak, a
range of 1.0 1.6 ppm was integrated in order to determine
lipid content. The chi-square test was used to analyse spec-
troscopic data, and difference rankings between means at a
statistically significant level were thus established. A p val-
ue of 0.05 was considered statistically significant. 
RESULTS
A resonance peak at 1.3 ppm, caused by the presence of
the methylene group in fatty acid chains, was observed in
five of the seven malignant ovarian tumors and seven of
the eleven benign teratomas (Figs. 1, 4), as well as in one
borderline malignant tumor and the case of salpingitis (Fig.
2). Interestingly, whereas most primary and secondary ma-
lignant ovarian tumors showed an intense lipid peak at 1.3
ppm, this same peak was not observed in the MR spectra
of any of the six benign ovarian epithelial tumors (Fig. 3).
Thus, the incidence of a lipid peak was significantly higher
in malignant tumors than in benign epithelial tumors (p <
0.05). A lipid peak at 5.2 ppm, due to the presence of the
olefine group in fatty acid chains, was observed in two cas-
es of the eleven benign teratomas, one of the four en-
dometrioses, and the ectopic pregnancy. The 
1H- MR spec-
tra of benign ovarian epithelial tumors showed no de-
tectable lipid peak at 1.3 or 5.2 ppm (Tables 1, 2).
The lipid/water ratio was determined in 26 cases and was
smaller than 0.020 in 21 of these. The lipid/water ratios of
benign teratomas showed great variation, and some were
higher than those of other adnexal lesions. In addition, all
five cases in which the lipid/water ratio was greater than
0.020 were benign teratomas (p < 0.05).
Cho et al.
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Fig. 2. Patient 8. Borderline malignant mucinous cystic tumor in a 29-year-old woman. (A) Pelvic post-contrast CT scan and (B) axial
scanogram obtained using 
1H- MRS show a large multiseptated cystic mass with nodular enhancing peripheral portions. A prominent
lipid peak was noted at 1.3 ppm in (C) water-unsuppressed and (D) water-suppressed spectra, and the lipid-to-water ratio was 0.006.
CDDISCUSSION
In our study, 
1H- MR spectroscopic patterns differed
markedly according to the histopathologic diagnosis of the
adnexal lesions. In fatty acid chains, the presence of the
methylene group caused a resonance peak at 1.3 ppm in
most patients with malignant ovarian tumors, benign ter-
atomas and salpingitis. However, no lipid peak at 1.3 ppm
was found in the 
1H- MR spectra of benign ovarian epithe-
lial tumors or endometrioses.
In many previous studies involving in-vivo and ex-vivo
MRS of brain tumors and uterine cervical carcinomas, the
resonance peak due to fatty acid chains has been suggested
as a possible cancer marker (12 14); the results of our
study also support this possibility. Interestingly, Gotsis et
al. (14) reported that 
1H- MRS demonstrated the presence
of lipids in malignant brain tumors, abscesses and epider-
moid cysts, but not in benign brain tumors. They assumed
that necrosis and lipid formation might be the result of tu-
mor proliferation without a neovascular network sufficient
for its metabolic needs. Kuesel et al. (12) used ex-vivo
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Fig. 3. Patient 11. Mucinous cystadenoma in a 28-year-old woman. (A) Post-contrast CT scan and (B) axial scanogram obtained using
1H- MRS demonstrate a large multiseptated cystic pelvic mass. There was no prominent lipid peak at 1.3 ppm in either (C) water-unsup-
pressed or (D) water-suppressed spectra, and the lipid-to-water ratio was unavailable.
CD
Table 2. Comparison of Peaks and Lipid/Water Ratios in MR
Spectroscopy of Various Ovarian Lesions
No. of Cases Showing
Histopathologic Peaks at MRS Lipid/
Diagnosis Lipid peak Lipid peak Water Ratio
at 1.3 ppm at 5.2 ppm
Malignant tumor 5/7 0/7 0.007 0.001
Borderline malignant tumor 1/1 0/1 0.006
Benign epithelial tumor 0/6 0/6 0.007 0.002
Endometriosis 0/4 1/4 0.006 0.001
Benign teratoma 7/11 2/11 0.101 0.138
Salpingitis 1/1 0/1 0.010
Ectopic pregnancy 0/1 1/1 0.010
Note.─ statistical significance (p < 0.05), as determined by the chi-
square test;    mean 1 standard deviation1H- MRS to evaluate mobile lipid resonance at biopsy or in
surgical specimens of cerebral astrocytomas, discovering
that in high-grade tumors, 
1H- MRS is able to detect high
lipid levels. Rapid cellular turnover in malignant tissue usu-
ally leads to considerable cellular death, resulting in cellu-
lar necrosis, which appears in in-vivo
1H- MR spectra as a
lipid signal. This was previously observed in a study of hu-
man cervical carcinoma using in-vivo
1H- MRS; invasive
cervical carcinoma could be differentiated from normal
cervix by a peak at 1.3 ppm, with 89% sensitivity and
57% specificity (13). In our study, a 
1H- MR spectral peak
at 1.3 ppm was detected in malignant or borderline malig-
nant ovarian tumors, with 75% sensitivity (6/8) and 65%
specificity (15/23).
Because the T2 values of fatty acids and macromolecules
are very short, 
1H- MRS using a short TE is required for the
detection of these molecules. Owing to overlap in the spec-
tral peaks demonstrated by macromolecules and lipids, the
peaks obtained with short TE values (< 40 msec) are not as
well resolved as those obtained with TE values greater
than 90 msec (15 17). To avoid overlap between a lipid
peak and one due to other metabolites at 1.3 ppm, the
peak at 5.3 ppm caused by the presence of olefine has
sometimes been used to identify the lipid component of a
tumor (12). However, it can be assumed that because the
baseline of the spectrum is relatively flat, the peaks occur-
ring at about 1.3 ppm in the short TE MR spectrum of the
human ovary are due mainly to the presence in fatty acid
chains of the methylene group, and possibly lactate, but
not macromolecules. According to a report by Massuger et
al. (11), in-vitro
1H- NMR studies of ovarian cystic fluids
have disclosed that the amount of metabolites such as lac-
tate, methionine, pyruvic acid, and 3-hydroxybutylic acid
found in malignant cysts was over six times greater than in
Cho et al.
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Fig. 4. Patient 21. Benign mature cystic teratoma in a 23-year-old woman. (A) Transaxial T1-weighted (TR/TE=483/9) image and (B)
axial scanogram obtained using 
1H- MRS show a large pelvic mass with a heterogeneous internal texture. The focal, bright, high signal
intensity of the tumor indicates its fat component. A very prominent lipid peak at about 1.3 ppm in (C) water-unsuppressed and (D) water-
suppressed spectra was apparent, and the lipid-to-water ratio was 0.319.
CDbenign cysts. In our study, however, the only MR spectral
difference between benign and malignant ovarian tumors
was the lipid peak at 1.3 ppm. Numerous metabolites, in-
cluding amino acids, fatty acids, and other small molecules
are found in ovarian cysts, but due to their limited concen-
tration (i.e. sensitivity) and intrinsic properties such as T1
and T2 relaxation times, in-vivo
1H- MRS was able to de-
tect only a limited variety. Thus, in our study, we assumed
that the peaks occurring at 1.3 ppm were due mainly to a
tumor’s lipid component. Evidence which also supported
our assumption was the occurrence of a prominent peak at
1.3 ppm in most benign mature cystic teratomas in our
study. 
The combination of long- and short-TE spectra may be
useful for evaluating the presence within a tumor of
metabolites, lipids, and macromolecules (18). In studies of
brain and uterine cervical tumors, 
1H- MRS using long TE
has been used to detect long-T2 lipid components: nonma-
lignant cells of normal lipid have a short T2 value and are
thus apparent only in the spectrum of short TE. Lipid com-
ponents in a malignant tumor, on the other hand, assumed
to have a long T2 (> 400 msec), can be detected by long-
TE 
1H- MRS (13, 14, 19). The lipid peak thus detected is
therefore attributed to malignant ovarian tissues with long
T2 values, and this may indeed imply that the 
1H-MR spec-
troscopic technique is sensitive to early cellular change. In
the case of pelvic MRS examination, signal intensity is in-
fluenced by motion artifact caused by respiratory and peri-
staltic bowel movement; an NMR study reported that the
high susceptibility of the volume localization sequence to
motion was a major disadvantage of short-TE STEAM 
1H-
MRS (20). Hence we used both short- and long-TE MRS at
the beginning of this study, but found that the waveforms
of long-TE MR spectra were very irregular and non-infor-
mative, probably due to artifact. Long- and short-TE MRS
data could not be combined, and only short-TE MR spectra
could be analysed.
Only a few studies using 
1H- MRS have tried to differen-
tiate between ovarian tumors and other pelvic lesions (11,
13, 21). In order to avoid the broad disturbing spectral res-
onances caused by protein protons, Massuger et al. (11) re-
cently analysed in-vitro
1H- NMR data of deproteinized
ovarian cyst fluid samples. The in-vitro
1H- NMR spectra
obtained showed significant differences in metabolite con-
centrations between benign and malignant ovarian cysts,
and significantly higher levels of lactate, isoleucine, valine,
3-hydroxybutylic acid, methionine and alanine were de-
tected in malignant epithelial ovarian cysts. According to
them, the elevated metabolite level and branched-chain
amino acids found in malignant ovarian tumors most likely
result from anaerobic glycolysis and enhanced proteolysis.
In our study, however, these peaks were not usually de-
tected by in-vivo
1H- MR spectroscopy because the mini-
mal concentration detectable by 1.5-T MR instruments is
currently tens of millimoles.
Although various lesions in our study demonstrated a
lipid peak at 1.3 ppm, the lipid/water ratio was useful to
differentiate ovarian lesions. As they can be diagnosed eas-
ily by the detection of a lipid component at CT or MRI,
teratomas demonstrated characteristically greater lipid/wa-
ter ratios than other ovarian lesions; all our five cases in
which the lipid/water ratio was greater than 0.020 were
teratomas. 
This study has several limitations, one of which is that
1H- MR spectroscopic and radiologic findings were not
compared. Another is the small number of cases studied. In
order to establish indications of in-vivo
1H- MR spectro-
scopic diagnosis, further investigation involving a large
number of cases is required.
In conclusion, various ovarian lesions can be distin-
guished by careful disclosure of in-vivo
1H- MR spectra,
and in-vivo
1H- MRS is potentially able to discriminate be-
tween malignant and benign tumors. The presence of a
lipid peak at 1.3 ppm is a useful indicator of malignancy.
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